Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab plus chemotherapy versus placebo plus chemotherapy in recurrent platinum-resistant epithelial ovarian cancer with low HER3 mRNA
NL-OMON36976Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Apr 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pertuzumab in ovarian cancer and epithelial ovarian cancer (EOC), sponsored by Roche. Started Apr 2013; status: active, not recruiting.
02
Drugs
pertuzumab
03
Conditions
ovarian cancerepithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NL-OMON36976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36976.